Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab

MLA

Hirokazu Abe, et al. “Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (IRECIST) with RECIST for Capturing Treatment Response of Patients with Metastatic Urothelial Carcinoma Treated with Pembrolizumab.” BJU International, vol. 127, Aug. 2020, pp. 90–95. EBSCOhost, https://doi.org/10.1111/bju.15176.

APA

Hirokazu Abe, Takahiro Kimura, Yuya Iwamoto, Yuhei Koike, Takafumi Yanagisawa, Yuki Enei, Shin Egawa, Masatoshi Tanaka, Mariko Honda, Wataru Fukuokaya, Hajime Onuma, Yu Oyama, Jun Miki, Fumihiko Urabe, Shunsuke Tsuzuki, & Shoji Kimura. (2020). Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. BJU International, 127, 90–95. https://doi.org/10.1111/bju.15176

Chicago

Hirokazu Abe, Takahiro Kimura, Yuya Iwamoto, Yuhei Koike, Takafumi Yanagisawa, Yuki Enei, Shin Egawa, et al. 2020. “Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (IRECIST) with RECIST for Capturing Treatment Response of Patients with Metastatic Urothelial Carcinoma Treated with Pembrolizumab.” BJU International 127 (August): 90–95. doi:10.1111/bju.15176.